Lilly, Amgen Seek Fast Win in Suit Over Clinics in Discount Plan

Eli Lilly & Co., Amgen Inc., and UCB Inc. are urging a federal district court to rule that a federal health agency acted unlawfully when it allowed certain clinics to obtain their discounted medicines through a government pricing program.

The drugmakers’ motion for summary judgment filed March 20 asks the US District Court for the District of Columbia to set aside the Health Resources and Services Administration’s certifications and recertifications of Sagebrush Health Services for participation in the 340B Drug Pricing Program.

“HRSA has rubber-stamped applications based on little more than a cursory email from a state health ...